Basiliximab

Names

[ Name ]:
Basiliximab

Biological Activity

[Description]:

Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation[1].

[Related Catalog]:

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Research Areas >> Inflammation/Immunology

[Target]

Interleukin-2 receptor[1]

[In Vitro]

Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα[1]. Basiliximab binds only to activated lymphocytes and macrophages/monocytes[3]. Basiliximab does not affect resting T lymphocytes that do not express IL-2Rα[3].

[In Vivo]

Basiliximab (CHI 621) (0.07 mg/rat; i.v.; once) decreases total placental natural killer cells in reduced uterine perfusion pressure (RUPP) rats[2]. Animal Model: Timed-pregnant Sprague Dawley (SD) rats, reduced uterine perfusion pressure (RUPP) rat model of placental ischemia[2] Dosage: 0.07 mg/rat Administration: IV infusion, once Result: Decreased total placental natural killer cells. Had no effect to lower MAP or improve pup weight and placental weight.

[References]

[1]. McKeage K, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs. 2010 Feb 1;24(1):55-76.

[2]. Cunningham M W, et al. The Role of Interleukin‐2 (IL‐2) in Natural Killer Cell (NK) Activation and Hypertension in a Preclinical Rat Model of Preeclampsia. The FASEB Journal, 2018, 32: 911.1-911.1.

[3]. Chapman TM, et al. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.